GB1054278A - Pharmaceutical preparations having hypoglycaemic properties - Google Patents

Pharmaceutical preparations having hypoglycaemic properties

Info

Publication number
GB1054278A
GB1054278A GB4461864A GB4461864A GB1054278A GB 1054278 A GB1054278 A GB 1054278A GB 4461864 A GB4461864 A GB 4461864A GB 4461864 A GB4461864 A GB 4461864A GB 1054278 A GB1054278 A GB 1054278A
Authority
GB
United Kingdom
Prior art keywords
alkyl
lower alkoxy
alkoxy
sulphonamide
nov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4461864A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba AG filed Critical Ciba AG
Publication of GB1054278A publication Critical patent/GB1054278A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1,054,278. Hypoglycemic compositions containing sulphonamides. CIBA Ltd. Nov. 2, 1964 [Nov. 5, 1963; Sept. 17, 1964], No. 44618/64. Heading A5B. [Also in Division C2] Pharmaceutical compositions comprise a sulphonamide of formula: or an N-acyl derivative or physiologically acceptable salt thereof, wherein Ph and Ph' each represent a substituted or unsubstituted phenyl group; R" is hydrogen, lower alkyl, lower alkoxy, lower alkoxy-lower alkyl, lower alkoxy-lower alkoxy, cyclo-alkyl, or substituted or unsubstituted phenyl or pyridyl; and R' is as for R", or is halogen, or R' together with R" represent an alkylene group, providing that when Ph»SO 2 »NH» is parasulphanilamido, than at least one of R' and R" is not hydrogen, in admixture or conjunction with a benzenesulphonylurea capable of lowering the blood sugar level, and whose phenyl group carries a methyl group. The term "lower" in qualifying alkyl, alkylene, alkoxy and alkanoyl groups and aliphatic carboxylic acids is used to mean groups and compounds containing up to 6 carbon atoms. Examples are given for preparing compositions of the active agents in oral unit dosage form with conventional excipients, and also for preparation of the active ingredients (see Division C2). The sulphonamide is said to delay the biological degradation of the sulphonyl-urea in vivo, and thus to potentiate the action of the latter.
GB4461864A 1963-11-05 1964-11-02 Pharmaceutical preparations having hypoglycaemic properties Expired GB1054278A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1359863 1963-11-05
CH1210364 1964-09-17

Publications (1)

Publication Number Publication Date
GB1054278A true GB1054278A (en) 1967-01-11

Family

ID=25709624

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4461864A Expired GB1054278A (en) 1963-11-05 1964-11-02 Pharmaceutical preparations having hypoglycaemic properties

Country Status (5)

Country Link
BE (1) BE655242A (en)
DE (1) DE1467832A1 (en)
FR (2) FR3797M (en)
GB (1) GB1054278A (en)
NL (1) NL6412822A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506910A (en) * 2013-01-17 2016-03-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Oxytocin receptor agonists for the treatment of CNS diseases
RU2579515C1 (en) * 2014-12-29 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный технологический университет" (СибГТУ) Alkoxymethyl-substituted 1h-4-aminopyrazoles

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3503609A1 (en) * 1985-02-02 1986-08-07 Bayer Ag, 5090 Leverkusen 5-SULPHONAMIDO-1-ARYL-PYRAZOLE
WO2013046041A1 (en) 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506910A (en) * 2013-01-17 2016-03-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Oxytocin receptor agonists for the treatment of CNS diseases
RU2664705C2 (en) * 2013-01-17 2018-08-21 Ф. Хоффманн-Ля Рош Аг Oxytocine receptor agonists for the central nervous system diseases treatment
RU2579515C1 (en) * 2014-12-29 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный технологический университет" (СибГТУ) Alkoxymethyl-substituted 1h-4-aminopyrazoles

Also Published As

Publication number Publication date
NL6412822A (en) 1965-05-06
DE1467832A1 (en) 1968-11-28
FR4034M (en) 1966-03-28
BE655242A (en) 1965-05-04
FR3797M (en) 1965-12-27

Similar Documents

Publication Publication Date Title
MY101791A (en) New benzimidazole derivatives
DE3271269D1 (en) Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same
KR970704710A (en) Triazole compounds and their use as dopamine D3 ligands (Triazole Compounds and Their Use as Dopamine-D3-Ligands)
KR910015562A (en) Drugs for the treatment of brain failure diseases, novel 2- (1-piperazinyl) -4-phenylcycloalkano pyrimidine derivatives, and preparations thereof
GB1180766A (en) 2-Arylamine-1,3-Diazacycloalkenes-(2) and the Preparation Thereof
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
GB1185522A (en) 00,5-(Iminomethano)-10,11-Dihydro-5H-Dibenzo [a,d]Cycloheptene and Derivatives
GB1054278A (en) Pharmaceutical preparations having hypoglycaemic properties
SE7310986L (en) PROCEDURE FOR PREPARING THE SUBJECT LEMPLIGA SASOM TOYS.
GB1180794A (en) Novel Arylhydrazino-Imidazolines and Preparation Thereof
US2407412A (en) Therapeutic solutions
GB1322451A (en) 3-amino-5-benzyl-1,2,4-oxadiazoles
GB1354451A (en) Halogen-substituted phenyl-alkylamines and their derivatives
GB1497729A (en) Benzenesulphonyl ureas and process for their manufacture
ES486049A1 (en) Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-ones, process for their preparation, and pharmaceutical compositions containing them.
RU95107147A (en) Cyclohexanecarboxylic acid derivatives, mixture of isomers thereof or individual isomers and physiologically tolerable salts, and pharmaceutical composition having activity which inhibits enzymic glucose-phosphotase complex of liver
GB1177145A (en) Heterocyclic Allylic Amines
GB1382787A (en) Aryl-piperazine derivatives of adenine
GB1174988A (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same
GB1353520A (en) Diphenyl sulphones
GB1180120A (en) Pharmaceutical Compositions Containing Alkaloids.
GB1430411A (en) Method and compositions for combating swine dysentery
GB1321368A (en) Organo-phosphorus compounds useful for the control of helminths in warm-blooded animals
GB1313274A (en) Bicycloalkanecarboxymides and the preparation thereof
GB1311618A (en) 4-sulphanilyl phenyl urea complexes